Probiotic administration in congenital heart disease: A pilot study

C. L. Ellis, N. A. Bokulich, K. M. Kalanetra, M. Mirmiran, J. Elumalai, L. Haapanen, T. Schegg, John C Rutledge, Gary W Raff, D. A. Mills, Mark Underwood

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Objective:To investigate the impact of probiotic Bifidobacterium longum ssp. infantis on the fecal microbiota and plasma cytokines in neonates with congenital heart disease.Study design:Sixteen infants with congenital heart disease were randomly assigned to receive either B. infantis (4.2 × 10 9 colony-forming units two times daily) or placebo for 8 weeks. Stool specimens from enrolled infants and from six term infants without heart disease were analyzed for microbial composition. Plasma cytokines were analyzed weekly in the infants with heart disease.Results:Healthy control infants had increased total bacteria, total Bacteroidetes and total bifidobacteria compared to the infants with heart disease, but there were no significant differences between the placebo and probiotic groups. Plasma interleukin (IL)10, interferon (IFN)γ and IL1β levels were transiently higher in the probiotic group.Conclusion:Congenital heart disease in infants is associated with dysbiosis. Probiotic B. infantis did not significantly alter the fecal microbiota. Alterations in plasma cytokines were found to be inconsistent.

Original languageEnglish (US)
Pages (from-to)691-697
Number of pages7
JournalJournal of Perinatology
Issue number9
StatePublished - Sep 2013


  • bifidobacteria
  • congenital heart disease
  • microbiota
  • necrotizing enterocolitis
  • probiotic

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Probiotic administration in congenital heart disease: A pilot study'. Together they form a unique fingerprint.

Cite this